Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia (Bortezomib)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2011 by Clinical Service, China.
Recruitment status was  Recruiting
Harbin Institute of Hematology and Oncology
Shanghai Changzheng Hospital
Chinese PLA General Hospital
Affiliated Hospital to Academy of Military Medical Sciences
Wuhan Union Hospital, China
Beijing Chao Yang Hospital
Henan Provincial Hospital
Peking University Third Hospital
Information provided by (Responsible Party):
wangzhao, Clinical Service, China Identifier:
First received: March 29, 2011
Last updated: September 21, 2011
Last verified: September 2011
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: September 2015
  Estimated Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)